Factory For Lovastatin - Eptifibatide for Treatment of Acute Coronary Syndrome 188627-80-7 – Gentolex

Short Description:

Send email to us

Product Detail

Product Tags

Feedback (2)

We can normally fulfill our respected consumers with our great excellent, great value and good provider due to we're much more specialist and extra hard-working and do it in cost-effective way for Lurasidone Hydrochloride, N-Ethoxycarbonyl-4-Piperidinone, Local Anesthetic, Adhering to the business philosophy of 'customer first, forge ahead', we sincerely welcome clients from at home and abroad to cooperate with us.

Factory For Lovastatin - Eptifibatide for Treatment of Acute Coronary Syndrome 188627-80-7 – Gentolex Detail:

Product Detail

Name	Eptifibatide
CAS number	188627-80-7
Molecular formula	C35H49N11O9S2
Molecular weight	831.96
EINECS Number	641-366-7
Density	1.60±0.1 g/cm3(Predicted)
Storage conditions	Sealed in dry, store in freezer, under -15°C

Synonyms

Eptifibatideacetatesalt;Eptifibatide,MPA-HAR-Gly-Asp-Trp-Pro-Cys-NH2,MPAHARGDWPC-NH2,>99%;MAP-LYS-GLY-ASP-TRP-PRO-CYS-NH2;INTEGRELIN;Eptifibatide;N6-(Aminoiminomethyl)-N2-(3-mercapto-1-oxopropyl-L-lysylglycyl-L-a-aspartyl-L-tryptophyl-L-prolyl-L-cysteinamide;MPA-HAR-GLY-ASP-TRP-PRO-CYS-NH2(DISULFIDEBRIDGE,MPA1-CYS6).

Platelet Glycoprotein Antagonist

Etifibatide (integrilin) is a novel polypeptide platelet glycoprotein IIb/IIIa receptor antagonist, which inhibits platelet aggregation and thrombosis by inhibiting the last common pathway of platelet aggregation. Compared with the monoclonal antibody abciximab, eptifibatide has a stronger, more directional and specific binding to GPIIb/IIIa due to the existence of a single conservative amino acid substitution—lysine to replace arginine. Therefore, it should have a good therapeutic effect in the interventional treatment of acute coronary syndrome. Platelet glycoprotein IIb/IIIa receptor antagonist drugs have been developed a lot, and currently there are 3 kinds of preparations that can be used in clinical internationally, abciximab, eptifibatide and tirofiban. ). There is little experience in the use of platelet glycoprotein GPIIb/IIIa receptor antagonists in China, and the available drugs are also very limited. Only one drug, tirofiban hydrochloride, is on the market. Therefore, a new platelet glycoprotein IIb was developed. /IIIa receptor antagonists are imperative. Domestic eptifibatide is an imitation product produced by Chengdu Sino Biological Products Co., Ltd.

Classification

Classification of Antiplatelet Aggregation Drugs

Antiplatelet aggregation drugs can be roughly divided into three categories: 1. Cyclooxygenase-1 (COX-1) inhibitors, such as aspirin. 2. Inhibit platelet aggregation induced by adenosine diphosphate (ADP), such as clopidogrel, prasugrel, cangrelor, ticagrelor, etc. 3. Platelet glycoprotein Ⅱb/Ⅲa receptor antagonists, such as abciximab, eptifibatide, tirofiban, etc. In addition, there are prostaglandin EP3 receptor inhibitors, newly synthesized chemical components and effective extracts from traditional Chinese medicine.

Product detail pictures:

Related Product Guide:

We provide fantastic energy in top quality and advancement,merchandising,gross sales and marketing and operation for Factory For Lovastatin - Eptifibatide for Treatment of Acute Coronary Syndrome 188627-80-7 – Gentolex , The product will supply to all over the world, such as: Mauritania, Jakarta, Rome, After years' creating and developing, with the advantages of trained qualified talents and rich marketing experience, outstanding achievements were gradually made. We get good reputation from the customers due to our good products quality and fine after-sale service. We sincerely wish to create a more prosperous and flourishing future together with all the friends home and abroad!

Amisulpride